<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265927</url>
  </required_header>
  <id_info>
    <org_study_id>IUCRO-0314</org_study_id>
    <secondary_id>1010-05</secondary_id>
    <nct_id>NCT01265927</nct_id>
  </id_info>
  <brief_title>A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer</brief_title>
  <official_title>A Phase I Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Breast Cancer Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Geron Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate safety and biologic effects of giving GRN163L in combination with&#xD;
      trastuzumab in patients diagnosed with HER2+ metastatic breast cancer that is resistant to&#xD;
      therapy with trastuzumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the dose-limiting toxicity of GRN163L in combination with trastuzumab in patients with refractory HER2+ metastatic disease</measure>
    <time_frame>End of Study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the concentration of trastuzumab and GRN163L from blood samples immediately before and after infusion on day 1, weekly during cycle 1, and immediately prior to cycle 2</measure>
    <time_frame>Until cycle 2</time_frame>
    <description>PK data will be described using means, standard deviations, medians, minimums and maximums.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor biopsy and bone marrow aspirate assayed for telomerase activity prior to treatment and immediately prior to planned cycle 2</measure>
    <time_frame>Until cycle 2</time_frame>
    <description>Telomerase activity data will be described using means, standard deviations, medians, minimums and maximums.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow cytometry to compare cell cycle distribution in tumor and bone marrow prior to treatment and immediately prior to cycle 2.</measure>
    <time_frame>Until cycle 2</time_frame>
    <description>Marrow (and tumor when sufficient sample is available) will be analyzed via flow cytometry to determine cell distribution. Percentage of cells at each cycle will be described using means, standard deviations, medians, minimums and maximums.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor samples analyzed for activation of HER2 family signaling protein activation (phosphorylation) status prior to treatment and immediately prior to cycle 2.</measure>
    <time_frame>Until cycle 2</time_frame>
    <description>HER2 family signaling protein activation will be described using means, standard deviations, medians, minimums and maximums.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine objective response rate (ORR) and progression free survival (PFS) of GRN163L in combination with trastuzumab in this patient population</measure>
    <time_frame>End of Study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>GRN163L + Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRN163L in combination with trastuzumab</intervention_name>
    <description>GRN163L will be administered in escalating dose cohorts on Day 1 of each 21-day cycle prior to trastuzumab infusion. Trastuzumab will be a administered day 1 of each 21-day cycle after GRN163L. There will be a 30 minute observation period between the end of the GRN163L infusion and the beginning of the trastuzumab infusion.</description>
    <arm_group_label>GRN163L + Trastuzumab</arm_group_label>
    <other_name>Imetelstat Sodium</other_name>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females 18 years or older at the time of consent.&#xD;
&#xD;
          2. ECOG performance status of 0-2 within 21 days of study registration.&#xD;
&#xD;
          3. Histologically or cytologically confirmed adenocarcinoma of the breast with locally&#xD;
             recurrent or metastatic disease. NOTE: locally recurrent disease must not be amenable&#xD;
             to surgery or radiation with curative intent.&#xD;
&#xD;
          4. Measurable or evaluable disease according to RECIST v1.1 within 35 days prior to study&#xD;
             registration.&#xD;
&#xD;
          5. Disease must be amenable to biopsy (image-guided or via direct visualization of&#xD;
             superficial lesions) with minimal risk to the patient. NOTE: Patients with disease&#xD;
             limited to the lung and/or pleura are excluded.&#xD;
&#xD;
          6. Disease must be HER2+ as defined by IHC 3+ or FISH ratio &gt; 2.0.&#xD;
&#xD;
          7. Resistant to trastuzumab as defined as (1) progression within 12 months of completing&#xD;
             adjuvant/neoadjuvant trastuzumab or (2) progression on trastuzumab administered for&#xD;
             metastatic disease.&#xD;
&#xD;
          8. Prior treatment with lapatinib or investigational HER2 targeted therapies is allowed&#xD;
             but not required. There are no limits on the number of regimens or other prior&#xD;
             anti-HER2 therapies patients have received.&#xD;
&#xD;
          9. LVEF ≥ Lower Limit of Normal based on MUGA or ECHO within 35 days prior to study&#xD;
             registration&#xD;
&#xD;
         10. Females of childbearing potential and males must be willing to use an effective method&#xD;
             of contraception from the time consent is signed until 6 months after treatment&#xD;
             discontinuation. Methods of contraception include hormonal birth control (oral&#xD;
             contraceptives, patch, injection, vaginal ring or implant), two barrier methods of&#xD;
             birth control, abstinence and/or other methods as determined by the treating&#xD;
             physician.&#xD;
&#xD;
         11. Females of childbearing potential must have a negative pregnancy test within 14 days&#xD;
             prior to registration for protocol therapy.&#xD;
&#xD;
             NOTE: Females are considered of child bearing potential unless they are surgically&#xD;
             sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral&#xD;
             oophorectomy) or they are postmenopausal (&gt; 12 months since last menses).&#xD;
&#xD;
             Laboratory values must be obtained within 21 days of study registration:&#xD;
&#xD;
         12. Absolute neutrophil count (ANC) ≥ 1.5 K/mm3&#xD;
&#xD;
         13. Platelets ≥ 100 K/mm3&#xD;
&#xD;
         14. Hemoglobin (Hgb) ≥ 9.0 g/dL (may be transfused)&#xD;
&#xD;
         15. Serum creatinine &lt; 3.0 mg/dL&#xD;
&#xD;
         16. Total Bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
         17. AST/SGOT ≤ 2.5 x ULN. If liver metastases is present, AST ≤ 5 x ULN&#xD;
&#xD;
         18. ALT, SGPT ≤ 2.5 x ULN. If liver metastases is present, ALT ≤ 5 x ULN&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
         19. No Investigational therapy within 4 weeks of study registration&#xD;
&#xD;
         20. No hormonal therapy within 2 weeks of study registration&#xD;
&#xD;
         21. No cytotoxic chemotherapy within 2 weeks of study registration.&#xD;
&#xD;
         22. No prior treatment with GRN163L&#xD;
&#xD;
         23. No prior history of severe reaction to trastuzumab, as determined by the treating&#xD;
             physician.&#xD;
&#xD;
         24. No history of clinically significant cardiac dysfunction, including:&#xD;
&#xD;
             Current uncontrolled hypertension (systolic &gt;150 mmHg and/or diastolic &gt;100 mmHg), or&#xD;
             unstable angina History of symptomatic CHF (Grade &gt;3 by NCI CTCAE or Class &gt;II by NYHA&#xD;
             criteria [see Appendix IV]) or serious cardiac arrhythmia requiring treatment within&#xD;
             12 months of study registration, with the exceptions of atrial fibrillation and&#xD;
             paroxysmal supraventricular tachycardia History of myocardial infarction within 6&#xD;
             months of study registration&#xD;
&#xD;
         25. No history of cerebrovascular accident within 12 months of study registration&#xD;
&#xD;
         26. No active CNS metastases. Patients with previously treated CNS metastases who do not&#xD;
             require chronic steroids or anticonvulsants are eligible.&#xD;
&#xD;
         27. Prior radiation therapy must not have involved &gt; 25% of bone marrow due to potential&#xD;
             myelosuppression with GRN163L. See bone marrow chart in Appendix III&#xD;
&#xD;
             NOTE: Radiation therapy within 2 weeks of study registration is not allowed.&#xD;
&#xD;
         28. Females must not be breastfeeding.&#xD;
&#xD;
         29. No clinically significant active infection, as determined by the treating physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathy Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>December 3, 2010</study_first_submitted>
  <study_first_submitted_qc>December 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2010</study_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Breast Tumors</keyword>
  <keyword>Cancer of Breast</keyword>
  <keyword>Cancer of the Breast</keyword>
  <keyword>Genes, HER-2</keyword>
  <keyword>Genes, HER2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Imetelstat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

